TLR4 and myeloid sarcoma: TLR4 expression was significantly increased in bone marrow mesenchymal stem cells (MSCs) and peripheral monocytes of MS, activating its downstream molecules STAT-1, NF-κB, P38, JNK and CREB, increasing the production of CXCL10 and promoting inflammatory responses (51).